Greenwich LifeSciences, Inc. (NASDAQ:GLSI) Sees Large Increase in Short Interest

Greenwich LifeSciences, Inc. (NASDAQ:GLSI) was the target of a large increase in short interest in the month of December. As of December 15th, there was short interest totalling 530,200 shares, an increase of 8.1% from the November 30th total of 490,400 shares. Approximately 9.0% of the shares of the stock are short sold. Based on an average daily trading volume, of 28,200 shares, the days-to-cover ratio is currently 18.8 days.

Greenwich LifeSciences Stock Performance

Shares of NASDAQ GLSI opened at $11.23 on Thursday. The firm has a market cap of $147.62 million, a PE ratio of -14.04 and a beta of 1.61. Greenwich LifeSciences has a one year low of $8.00 and a one year high of $21.44. The firm has a fifty day moving average of $13.29 and a 200 day moving average of $14.27.

Institutional Trading of Greenwich LifeSciences

Institutional investors and hedge funds have recently modified their holdings of the stock. Rhumbline Advisers purchased a new position in Greenwich LifeSciences in the 2nd quarter valued at about $117,000. Barclays PLC raised its holdings in shares of Greenwich LifeSciences by 323.3% during the third quarter. Barclays PLC now owns 8,560 shares of the company’s stock valued at $123,000 after acquiring an additional 6,538 shares during the last quarter. Garden State Investment Advisory Services LLC purchased a new position in shares of Greenwich LifeSciences in the third quarter valued at approximately $253,000. Bank of New York Mellon Corp acquired a new stake in shares of Greenwich LifeSciences in the second quarter worth approximately $264,000. Finally, State Street Corp increased its position in shares of Greenwich LifeSciences by 4.4% during the third quarter. State Street Corp now owns 71,408 shares of the company’s stock worth $1,026,000 after purchasing an additional 3,005 shares in the last quarter. Hedge funds and other institutional investors own 4.16% of the company’s stock.

Greenwich LifeSciences Company Profile

Greenwich LifeSciences, Inc, a clinical-stage biopharmaceutical company, develops novel cancer immunotherapies for breast cancer and other HER2/neu-expressing cancers. Its lead product candidate is GP2, an immunotherapy, which is in Phase III clinical trial to prevent breast cancer recurrences in patients who have previously undergone surgery.